• Lucid Diagnostics Inc LUCD.OQ reported a quarterly adjusted loss of 17 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -52 cents. The mean expectation of five analysts for the quarter was for a loss of 8 cents per share. Wall Street expected results to range from -9 cents to -7 cents per share.

• Revenue rose 51.7% to $1.26 million from a year ago; analysts expected $1.38 million.

• Lucid Diagnostics Inc's reported EPS for the quarter was a loss of 17 cents​.

• The company reported a quarterly loss of $23.63 million.

• Lucid Diagnostics Inc shares had fallen by 11.3% this quarter and lost 6.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 16.4% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"

• Wall Street's median 12-month price target for Lucid Diagnostics Inc is $3.00, about 66% above its last closing price of $1.02

This summary was machine generated from LSEG data May 14 at 11:59 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)